Laser Bioprinting Device and in Vivo Applications

Programme(s)
HORIZON.3.1 - The European Innovation Council (EIC) 

Topic(s)
HORIZON-EIC-2022-ACCELERATORCHALLENGES-01 - EIC Accelerator Challenge: Technologies for Open Strategic Autonomy
 
Call for proposal
HORIZON-EIC-2022-ACCELERATOR-01

Funding Scheme
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Grant agreement ID: 190195672

Objective
PhosPrint's D-LIB platform technology is based on a compact and automated laser bioprinter and protocols for high-speed and high-precision in-vivo printing of tissues with autologous human body characteristics.

The bioprinter relies on the Laser Induced Forward Transfer (LIFT) technique to accomplish highly accurate and cost-effective printing of tissues. The bioprinter system is associated with protocols for cell isolation from autologous biopsies, cell expansion in-vitro, and cell printing in-vivo.

This is a truly new approach that allows for real-time tissue engineering/repair in complex medical conditions. D-LIB capabilities will enable the introduction of a laser bioprinting technology in surgery operations, starting with enterocystoplasty/augmentation in cystectomy bladder cancer patients as the selected go-to-market application.